Trastuzumab binds HER2 on tumor cells and its Fc engages Fcγ receptors on NK cells and other effectors to trigger antibody‑dependent cellular cytotoxicity (ADCC), killing the HER2+ cells; may also contribute via complement activation and apoptosis from HER2 signaling blockade.